A B S T R A C T The bisphosphonates (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (Cl2MDP) effectively inhibit the accelerated bone resorption associated with some skeletal disorders, e.g., Paget's disease. However, it has not been established whether these compounds exert their inhibitory effect by rendering the bone mineral more resistant to degradation, by diminishing the activity of resorbing cells, or through some combination of both activities. In this study, we have tested these possibilities using an in vitro resorption assay system consisting of elicited rat peritoneal macrophages co-cultured with particles of 45Ca-labeled, devitalized rat bone. This assay system permits the quantitative assessment of the action of APD and Cl2MDP on the two major phases of bone resorption (cell-substrate attachment and osteolysis) under circumstances where the drugs are present continuously or, most importantly for the issues in question, after the separate pretreatment of the particles or the resorbing cells.
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Our data indicate that (a) Both APD and C12MDP at concentrations 25 X 106 M diminish macrophagemediated 45Ca release (i.e., bone resorption) in a log dose-dependent fashion. (b) A 10-min pretreatment of bone particles with either bisphosphonate (P-C-P) similarly inhibits resorptive activity, but is most pronounced with Cl2MDP. However, only APD is effective in reducing resorption when cells are preincubated (for 24 h) with P-C-P. (c) In cultures containing both labeled and unlabeled bone, significant inhibition occurs only when the labeled particles are coated with P-C-P (indicating that the action of P-C-P-treated bone is highly localized). (d) P-C-P does not diminish cell-bone particle attachment, an essential step in the resorptive process. On the other hand, delaying the addition of P-C-P until after cell-bone attachment is completed significantly reduces the resorption-inhibiting effect of these compounds. (e) C12MDP reduces culture DNA content in proportion to its inhibitory effect on resorption, and both the inhibitory and cytotoxic actions of this P-C-P are dependent upon the presence of bone. On the other hand, APD is cytotoxic only at very high concentrations (10-4 M), acts independently of the presence of bone, and inhibits resorption without killing cells.
We conclude that the mechanisms of action of APD and C12MDP are markedly different. C12MDP is a potent cytotoxin in the presence of bone and apparently exerts its inhibitory effect in this manner. APD is noncytotoxic at levels adequate to suppress resorption and, therefore, must inhibit macrophage activity by some other mechanism. Neither P-C-P appears to limit resorption by decreasing the solubility of mineralized bone matrix.
INTRODUCTION
Bisphosphonates (P-C-P)' are nonbiodegradable analogues of pyrophosphate (PPi) with a high binding affinity for hydroxylapatite crystals (1). Administration of P-C-P to experimental animals rapidly curtails bone resorption (2-4), and it is for this reason that these compounds are used in the treatment of clinical disorders characterized by increased bone degradation. For example, both disodium (3-amino-l-hydroxypropylidene)-1,1-bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (Cl2MDP) are effective in decreasing bone resorption in Paget's disease and in the osteolytic lesions associated with neoplastic bone disease (5) (6) (7) (8) . Interestingly, APD effectively decreases bone resorption in vivo at much lower doses than does C12MDP. There is no clear explanation for this difference in potency, but it may relate to the observed effects of APD on the mononuclear phagocyte system (9) . Cells of the mononuclear phagocyte system (MPS) have the potential to regulate osteoclast activity (e.g., by producing prostaglandin E2) and APD might alter this aspect of MPS function.
The basis for the resorption-inhibiting effects of P-C-P remains unknown, but given the binding affinity of these compounds for hydroxylapatite crystals, they may well act subsequent to accumulation on bone mineral surfaces. Once present on such surfaces, they may exert their inhibitory effect by (a) directly decreasing mineral solubility and ultimately the resorbability of bone matrix, (b) inhibiting the attachment of osteoclasts and other potential resorbing cells (macrophages, tumor cells) to bone surfaces, or (c) diminishing the resorption-related and/or general metabolic activity of osteoclasts and other osteolytic cells. Alternatively, circulating P-C-P may act directly on cells to block cell-bone attachment or resorption, without prior binding to mineral surface.
At present, there is little information regarding the relative biological significance of each of these possible mechanisms of P-C-P inhibition. It is known, for example, that P-C-P will inhibit the growth and dissolution of hydroxylapatite crystals in vitro (10, 11) . In addition, P-C-P have been shown to modify the metabolic activity of several different cell types grown in culture (12, 13) . However, in none of these cases have bone matrix (or mineral) and a cell with osteolytic potential been separately treated with P-C-P and then combined in such a way as to assess the subsequent I Abbreviations used in this paper: APD, (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate; Cl2MDP, disodium dichloromethylidene bisphosphonate; a-MEM, Eagle's minimal essential medium; M0, adherent cell; MPS, mononuclear phagocyte system; P-C-P, bisphosphonate(s); PPi, inorganic pyrophosphate. action of these compounds on the resorptive process.
In this study, we have explored the mechanism of action of C12MDP and APD using a recently developed, macrophage-based assay system for bone resorption (14) . With this system, it is possible to independently treat resorbing cells (elicited peritoneal macrophages) and bone mineral (devitalized rat bone particles) with P-C-P and to quantify the results of such treatment on the ability of the macrophages to bind and resorb bone. Our data indicate that APD and C12MDP do not alter the attachment of cells to bone but do inhibit macrophage-mediated resorption in a dose-dependent fashion. In the case of C12MDP, this inhibition is bone mineral dependent, occurs primarily subsequent to the accumulation of P-C-P on the bone crystal surface, and appears to be a manifestation of the cytotoxicity of this P-C-P. In the case of APD, on the other hand, the P-C-P is cytotoxic only at high concentration, acts independently of the presence of bone and inhibits resorption, at least in part, by a mechanism not yet defined but probably dependent upon the direct action of APD on cells. Neither P-C-P appears to affect resorption by reducing the solubility of the mineral phase of bone.
METHODS
Binding and resorption assays are performed as described (14) and are summarized as follows: Elicited peritoneal adherent cells (M0) were obtained from rats (Sprague-Dawley, ±150 g) 3 Karsten and Wollenberger (15) .
RESULTS
APD and C12MDP, when present throughout the entire assay period, reduced net 45Ca release from the bone particles in a log dose-dependent fashion. In the representative experiment shown in Fig. 1 , significant inhibition of resorption was achieved by both compounds at 5 X 106 M (P < 0.01). The molar potency of the two P-C-P was equal. (Fig. 3) . In marked contrast, only APD was effective in reducing macrophage-mediated resorption under circumstances where the cells were preincubated with P-C-P for 24 h (Table I) . Additional evidence for a direct involvement of bone surfaces in mediating the inhibitory action of P-C-P was obtained from experiments in which 45Ca-labeled and unlabeled bone were introduced concurrently into replicate M0-containing cultures. In some All values are means±SEM from six determinations. ' Significantly different from control, P < 0.01.
instances, the labeled particles were pretreated with P-C-P before being added to the wells; in other cases, it was the unlabeled bone that was coated with P-C-P. If P-C-P act primarily by their presence at the cell-bone interface, then only those wells containing labeled bone and P-C-P should show evidence of reduced resorptive activity. In the experiment depicted in Fig. 4 , the decrements in apparent resorptive activity were only significant in cultures containing labeled bone pretreated with P-C-P. We have previously demonstrated that binding of bone by MO is a prerequisite for resorption and that a lag period of -8 h exists between the initiation of 14- FIGURE 4 The co-culture of labeled and unlabeled bone "coated" with C12MDP or APD. In some instances the labeled bone (L) was pretreated (10 min) with 1i-0 M C12MDP or APD; in other cases the unlabeled bone (U) was pretreated. Notice that significant (*) inhibition of resorption (45Ca release) was evident only in those instances where the labeled particles were coated with P-C-P (P < 0.01, C12MDP; P < 0.001, APD). All values represent the mean±SEM from six determinations. binding and the onset of osteolysis (14, and unpublished observations). Table II shows that neither compound interferes with the binding of bone by the cells. However, deferring the introduction of P-C-P until after maximum cell-particle binding is achieved and bone degradation begins, significantly reduces the resorption-inhibiting effect of these compounds (Fig. 5 ). This effect was most notable with C12MDP where an 8-h delay totally eliminated the suppressive effect of this P-C-P. APD, on the other hand, continued to be Fig. 6 , in cultures containing bone particles and treated with C12MDP, for the 96-h assay period, there is a near proportionality between the degree of cytotoxicity (loss of DNA) and the extent of the inhibition. We noted earlier the effectiveness of pretreating bone particles with Cl2MDP in suppressing resorption (Fig. 2) . The critical importance of the bone particles in contributing to the action of Cl2MDP was further documented by experiments in which cytotoxicity was shown to vary as a function of both the amount and particle size of bone added to the cultures. From the experiment depicted in Fig. 7 , it can be seen that the decrement in the amount of DNA increases with increasing amounts of bone, and that smaller bone particles are approximately an order of magnitude more effective in enhancing cytotoxicity than are larger ones.
The relationship between cytotoxicity and the inhibition of resorption was much less certain with regard to APD and C12MDP. For example, in contrast to C12MDP, cultures treated continuously with APD exhibit relatively greater inhibition of resorption than loss of cells (Fig. 6) . Moreover, and again in distinction to Cl2MDP, the degree of cell death in APD-treated cultures was independent of the mode of presentation of the P-C-P and whether or not bone was present in the wells (Table III) . Finally, and perhaps most importantly, APD showed significant inhibition of resorption at concentrations lower than those needed to affect cell viability (loss of DNA; c.f., Fig. 6 ), and with a different time course of activity (Fig. 8) . DISCUSSION We mentioned previously that P-C-P bind to and limit the in vitro solubility of hydroxylapatite (bone) crystals (1, 10, 11) . It follows from this that P-C-P may inhibit bone resorption by directly increasing the resistance of the mineral phase of bone to degradation (16) . However, the inhibition of resorption by P-C-P is also associated with dramatic changes in both osteoclast morphology and in the size of the osteoclast population (2) (3) (4) 17) , indicating that these compounds exert a profound effect upon resorbing cells as well as upon the bone mineral.
To gain further insight into the relative importance of P-C-P action on mineralized bone matrix and resorbing cells, we have assessed the effect of these compounds using an in vitro assay system that permits the independent treatment of the cellular and matrical components of bone resorption. Specifically, w'e have determined the binding and resorption of isotopically labeled rat bone particles by elicited rat macrophages under conditions where the drugs were present continuously and following the preincubation of the cells or bone particles with P-C-P.
The suppression of 45Ca release in the continuous presence of Cl2MDP or APD documents the inhibitory effect of P-C-P on bone resorption in the macrophageresorption system. Moreover, the lack of change in the passive movement of 45Ca in the presence of either compound argues th'at this inhibition cannot be explained simply by crystal stabilization. Similarly, the effect of P-C-P on resorption does not appear to be due to a diminution in the' avidity with which resorbing cells bind the bone particles, a step that we have previously shown to be essential in the resorptive process (14) .
On the other hand, our data do indicate that the binding of P-C-P to bone mineral very likely plays an important role in the skeletal action of these compounds, at least with regard to Cl2MDP. For example, pretreatment of 45Ca-labeled bone particles with C12MDP suppresses subsequent resorptive activity almost as effectively as having the P-C-P present continuously in the culture medium. In addition, the observation that the inhibitory action of P-C-P is reduced by delaying their introduction into the culture suggests that the compounds lose at least some of their effectiveness if they are prevented from accumulating on crystals' surfaces until cell-matrix attachment is completed and resorption initiated. This observation is particularly striking in the case of Cl2MDP, where an 8-h delay entirely mitigates its inhibitory action. Finally, the data from the experiment utilizing treated unlabeled and labeled bone further establishes that mineral-bound P-C-P can directly suppress resorption without prior release of P-C-P from the bone surface or of some secondary effector substance (monokine) from macrophages.
The proportional diminution in the DNA content of adherent macrophage populations and resorptive activity indicates that cytotoxicity is largely responsible for the inhibitory effect of C12MDP on bone resorption, as has been previously suggested (18) . This cytotoxicity is dependent upon the presence of bone and, as we have shown here, increases when additional TIME (h ) FIGURE 8 Time course of the inhibition of resorption by 5 X lo-5 M C12MDP and APD. Note that both P-C-P show marginal inhibitory activity within the first 24 bone particles are added to the cultures. We noted above the importance of bone surfaces in "delivering" P-C-P. This aspect of P-C-P action is reinforced by the observation that smaller bone particles, with their substantial surface-to-volume ratio, are significantly more effective in enhancing cytotoxicity than are larger particles (even if the latter are present in much greater amounts).
In contrast to C12MDP, APD does not appear to inhibit macrophage-mediated resorption solely by killing the resorbing cells. For example, there is a poor correspondence between the loss of adherent macrophages and the inhibition of resorption in cultures treated with APD, and, in fact, significant inhibition is usually observed in the absence of a demonstrable cytotoxicity. Moreover, when cytotoxicity is encountered, it is at very high concentrations of APD (1lo M) and is independent of both the mode of introduction of the P-C-P and whether or not bone is present in the cultures.
APD and C12MDP do not behave identically in vivo (9) and other differences in the mechanisms of action of these compounds are evident in the present in vitro study. C12MDP appears to work as a cytotoxin in the presence of bone, and this seems adequate to account for the diminution in macrophage-mediated resorption reported above and, perhaps, in animals treated with this P-C-P. APD, on the other hand, suppresses resorption without killing the resorbing cells and without the intervention by bone. This latter effect is, perhaps, most notable in the delayed introduction experiments, where APD continues to exhibit significant inhibitory action even after the completion of cell-bone binding. Thus, while the precise mechanism of action of APD remains unknown, the fact that it can act directly on sensitive cells may account for the relatively greater in vivo potency exhibited by this compound when compared to other P-C-P, e.g., C12MDP and EHDP (1-hydroxyethylidene-l,1-bisphosphonate).
